&w=3840&q=100)
Nectar Lifesciences hits 52-week low; why are investors dumping stock?
The selling pressure came after the company's move to sell off its core business division to Ceph Lifesciences Private Limited disappointed investors.
In the exchange filing the company said that it has inked a definitive Business Transfer Agreement (BTA) for the sale of its core business division—comprising the manufacture, distribution, and marketing of active pharmaceutical ingredients (APIs) and formulations—to Ceph Lifesciences Private Limited, for a consideration of ₹1,270 crore, on a slump sale basis.
Additionally, the company has entered into an Asset Purchase Agreement (APA) for the sale of its menthol business assets to Ceph Lifesciences for ₹20 crore, marking a comprehensive restructuring move aligned with its future strategy.
"By divesting mature segments of our business, we are laying the foundation for a focused and agile organisation geared towards innovation and long-term value creation," Nectar Lifesciences Promoter and Chairman Sanjiv Goyal said.
The proceeds from the sale will be used to: repay existing debt, invest in new and emerging business areas, reward shareholders, subject to applicable approvals, and fund future corporate and growth initiatives.
The transaction was approved by the company's board on July 7, 2025, and is subject to shareholder approval at the Extraordinary General Meeting (EGM) to be held on August 4, 2025.
The transaction is expected to be completed on or before September 20, 2025, and there will be no change in the company's existing shareholding. ALSO READ |
About Nectar Lifesciences Limited
Nectar Lifesciences Ltd. is an established pharmaceutical company focused on research-driven innovation, manufacturing, and global distribution. The company is listed on the NSE and BSE and is committed to enhancing stakeholder value through disciplined strategy and operational excellence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
29 minutes ago
- Indian Express
SBI vs PNB vs Bank of Baroda vs Canara Bank: Which PSU bank offers high dividend, mcap and returns?
SBI vs PNB vs Bank of Baroda vs Canara Bank: Shares of some public sector banks (PSBs) have attracted the investors' attention due to a strong market rally and dividends. Here, we analyse and compare four PSU bank stocks across various parameters, including dividend payouts, market capitalisation, share prices, and long-term returns to help investors understand which offers the most value. Among the four, State Bank of India (SBI) holds the highest market capitalisation. As per NSE data (as of July 12), SBI – Rs 7,21,644.78 crore PNB – Rs 1,26,364.91 crore Bank of Baroda – Rs 1,22,535.43 crore Canara Bank – Rs 1,01,291.96 crore This makes SBI the largest PSB by market cap. As per the BSE record, SBI has declared a dividend of Rs 15.90 per share in 2025. PNB paid a Rs 2.90 per share dividend. Bank of Baroda announced dividend of Rs 8.35. Meanwhile, Canara Bank paid a dividend of Rs 4 to the equity shareholders. According to NSE (July 12), share price of SBI, PNB, Bank of Baroda and Canara Bank are Rs 808.60, Rs 109.95, Rs 236.95 and Rs 111.67 apiece, respectively. According to the BSE analytics, shares of SBI gave negative returns of 0.41 per cent, 0.79 per cent and 5.61 per cent in the last 1 week, 1 month and 1 year, respectively. In the past 2 years, 3 years, 5 years and 10 years, shares of the country's largest bank rose 37.39 per cent, 65.61 per cent, 313.24 per cent and 198.89 per cent, respectively. Shares of PNB fell 0.72 per cent, 0.23 per cent, 7.79 per cent and 24.10 per cent in the last 1 week, 1 month, 1 year and 10 years, respectively. However, shares of the bank gained in the past 2 years, 3 years, and 5 years by 82.08 per cent, 255 per cent, and 213.98 per cent, respectively, according to the BSE analytics. Bank of Baroda's shares gained in the past 1 week by 2.09 per cent. According to the BSE analytics, shares of Bank of Baroda fell 5.11 per cent and 9.13 per cent in the last 1 month and 1 year, respectively. In the past 2 years, 3 years, 5 years and 10 years, shares of the bank rose 32.24 per cent, 140.67 per cent, 539.12 per cent, and 53.87 per cent, respectively. Shares of Canara Bank gave negative returns of 2.14 per cent, 4.48 per cent and 1.97 per cent in the last 1 week, 1 month and 1 year, respectively. In the past 2 years, 3 years, 5 years, and 10 years, shares of the PSB climbed 68.35 per cent, 157.78 per cent, 434.91 per cent, and 96.54 per cent, respectively, according to the BSE analytics.
Business Standard
2 hours ago
- Business Standard
RVNL bags LoA for OHE upgradation project from
Rail Vikas Nigam (RVNL) has been awarded a letter of acceptance (LoA) by the South Central Railway for a significant project valued at Rs 213.22 crore. The contract encompasses the design, supply, erection, testing, and commissioning of an overhead equipment (OHE) upgradation project. This involves converting the existing 1x25kV system to a 2x25kV feeding system, including associated feeder and earthing works. The scope of work covers the Duvvada-Rajahmundry and Samalkot-Kakinada Port sections of the Vijayawada Division, falling under South Central Railway. The total length of the project spans 195.5 track kilometers (RKM) / 391 equivalent track kilometers (TKM). The domestic contract has to be executed within a period of 24 months. Rail Vikas Nigam is in the business of executing all types of railway projects, including new lines, doubling, gauge conversion, railway electrification, metro projects, workshops, major bridges, construction of cable-stayed bridges, institution buildings, etc. The company reported a 4.05% decrease in consolidated net profit to Rs 459.15 crore in Q4 FY25 as against Rs 478.56 crore posted in Q4 FY24. Revenue from operations slipped 4.27% YoY to Rs 6,426.88 crore in the quarter ended 31 March 2025. The scrip shed 0.81% to end at Rs 381.55 on the BSE on Friday.
Business Standard
2 hours ago
- Business Standard
Gland Pharma gets GMP certificate for Telangana-based facility from Danish Medicines Agency
Gland Pharma said that its Pashamylaram facility has received certificate of good manufacturing practices (GMP) compliance from Danish Medicines Agency. Pashamylaram is a village located in Patancheru mandal of Medak district in Telangana, India. This certification specifically covers the facility's production of aseptically prepared powder for injection, infusion, and inhalation. This GMP certificate is crucial for Gland Pharma as it pertains to marketing authorizations that list manufacturers located outside of the European Economic Area (EEA), allowing their products to be marketed within Denmark and potentially other EEA countries. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. The scrip had gained 0.89% to end at Rs 1859.05 on the BSE on Friday.
